Table 2.
Baseline and follow-up DAS28/RAPID3 scores based on group.
| TOTAL (N = 159) |
Biologic naïve (n = 65) |
Switch ABA IV→SC (n = 32) |
IR-bDMARD (n = 62) |
|---|---|---|---|
| DAS28-CRP | Median (IQR) | Median (IQR) | Median (IQR) |
| Baseline | 5.1 (2) | 2.4 (2) | 5.4 (2) |
| 6 months | 3.9 (2) | 2.8 (0) | 3.2 (2) |
| 12 months |
3.7 (3) |
2.7 (2) |
3.0 (2) |
| RAPID3 |
Median (IQR) |
Median (IQR) |
Median (IQR) |
| Baseline | 18.8 (8) | 12.7 (13) | 17.6 (8) |
| 6 months | 11.7 (10) | 11.9 (12) | 12 (10) |
| 12 months |
12.3 (10) |
12.3 (11) |
10.9 (10) |
| Linear mixed effect model | |||
| DAS28-CRP |
Estimate; 95% CI |
Estimate; 95% CI |
Estimate; 95% CI |
| Baseline | 4.97; 4.60–5.34 | 3.93; 3.25–4.61 | 4.85; 4.44–5.26 |
| 6 months | 3.64; 3.24–4.03 | 2.59; 1.91–3.28 | 3.52; 3.07–3.96 |
| 12 months |
3.67; 3.21–4.13 |
2.63; 1.95–3.31 |
3.55; 3.06–4.05 |
| RAPID3 |
Estimate; 95% CI |
Estimate; 95% CI |
Estimate; 95% CI |
| Baseline | 17.9; 16.22–19.62 | 13.4; 10.99–15.85 | 17.0; 15.26–18.76 |
| 6 months | 11.3; 9.58–13.06 | 12.3; 9.82–14.93 | 12.1; 10.28–14.07 |
| 12 months | 12.0; 10.22–13.78 | 11.6; 9.06–14.24 | 11.6; 9.59–13.62 |
Linear mixed effect model represents the average scores for DAS28 and RAPID3 based on time and group. Confidence intervals (CI) calculated with 95% confidence. ABA: abatacept; CRP: C-reactive protein; DAS28: Disease Activity Score; IQR: InterQuartile Range; IR-bDMARD: Inadequate Response to biological Disease-Modifying AntiRheumatic Drug; IV: intravenous; RAPID3: Routine Assessment of Patient Index Data 3; SC: subcutaneous; SES: socioeconomic status.